We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
Read MoreHide Full Article
AMN Healthcare Services, Inc. (AMN - Free Report) is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism led by a solid first-quarter 2023 performance and its healthcare Managed Services Program (“MSP”) are expected to contribute further. However, healthcare industry regulations and stiff competition are major downsides.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 2.2% compared with the 16.9% decline of the industry. The S&P 500 has witnessed 13.8% growth in the said time frame.
The renowned player in the healthcare total talent services space has a market capitalization of $4.29 billion. The company projects 3.3% growth for the next five years and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an earnings surprise of 10.5%, on average.
Image Source: Zacks Investment Research
Let’s delve deeper.
Broad Array of Services: We are optimistic about AMN Healthcare’s business’ gradual evolution beyond traditional healthcare staffing. The company has become a strategic total talent solutions partner for its clients. Its suite of healthcare workforce solutions includes MSPs, vendor management systems and medical language interpretation services.
On the first-quarter 2023 earnings call in May, management confirmed that the company is continuing to elevate AMN Passport to be a digital staffing solution for all healthcare jobseekers at any stage of their careers across all businesses of AMN Healthcare.
Healthcare MSP: AMN Healthcare’s unique MSP is helping the company gain market traction. Notably, the program helps streamline the entire workforce planning process, which facilitates the delivery of improved patient care. This has resulted in a large network of improved patient care and efficiency.
In 2022, AMN Healthcare had approximately $5.3 billion in spend under management through its MSPs, and approximately 64% of its consolidated revenues flowed through MSP relationships.
Strong Q1 Results: Per management, the Technology and Workforce Solutions and Physician and Leadership Solutions segments exceeded expectations in the first quarter of 2023. The continued strength in AMN Healthcare’s Language Services also looks promising. The expansion of the gross margin bodes well.
Downsides
Healthcare Industry Regulations: AMN Healthcare provides talent solutions and technologies on a contractual basis to its clients who pay the company directly. Accordingly, Medicare, Medicaid and insurance reimbursement policy changes generally do not directly impact the company. Nevertheless, reimbursement changes in government programs, particularly Medicare and Medicaid, can and do indirectly affect the demand and the prices paid for AMN’s services.
Stiff Competition: AMN Healthcare faces significant competition in the Medical Services industry. The company competes in national, regional and local markets for healthcare organization clients and healthcare professionals. In the nurse and allied healthcare staffing business, it competes with a few national competitors, along with numerous smaller, regional and local companies.
Estimate Trend
AMN Healthcare has been witnessing a positive estimate revision trend for 2023. Over the past 90 days, the Zacks Consensus Estimate for its earnings per share has moved 0.8% north to $8.35.
The Zacks Consensus Estimate for second-quarter 2023 revenues is pegged at $987.9 million, suggesting a 30.8% decline from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Hologic, Inc. (HOLX - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Hologic, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 5.1% for fiscal 2024. HOLX’s earnings surpassed estimates in all the trailing four quarters, with an average of 27.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic has gained 9.8% compared with the industry’s 8.8% rise in the past year.
HealthEquity, sporting a Zacks Rank #1 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 9.1%.
HealthEquity has gained 0.5% against the industry’s 16.9% decline over the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.5%. BSX’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.9%.
Boston Scientific has gained 40.7% against the industry’s 22.8% decline over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
AMN Healthcare Services, Inc. (AMN - Free Report) is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism led by a solid first-quarter 2023 performance and its healthcare Managed Services Program (“MSP”) are expected to contribute further. However, healthcare industry regulations and stiff competition are major downsides.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 2.2% compared with the 16.9% decline of the industry. The S&P 500 has witnessed 13.8% growth in the said time frame.
The renowned player in the healthcare total talent services space has a market capitalization of $4.29 billion. The company projects 3.3% growth for the next five years and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an earnings surprise of 10.5%, on average.
Image Source: Zacks Investment Research
Let’s delve deeper.
Broad Array of Services: We are optimistic about AMN Healthcare’s business’ gradual evolution beyond traditional healthcare staffing. The company has become a strategic total talent solutions partner for its clients. Its suite of healthcare workforce solutions includes MSPs, vendor management systems and medical language interpretation services.
On the first-quarter 2023 earnings call in May, management confirmed that the company is continuing to elevate AMN Passport to be a digital staffing solution for all healthcare jobseekers at any stage of their careers across all businesses of AMN Healthcare.
Healthcare MSP: AMN Healthcare’s unique MSP is helping the company gain market traction. Notably, the program helps streamline the entire workforce planning process, which facilitates the delivery of improved patient care. This has resulted in a large network of improved patient care and efficiency.
In 2022, AMN Healthcare had approximately $5.3 billion in spend under management through its MSPs, and approximately 64% of its consolidated revenues flowed through MSP relationships.
Strong Q1 Results: Per management, the Technology and Workforce Solutions and Physician and Leadership Solutions segments exceeded expectations in the first quarter of 2023. The continued strength in AMN Healthcare’s Language Services also looks promising. The expansion of the gross margin bodes well.
Downsides
Healthcare Industry Regulations: AMN Healthcare provides talent solutions and technologies on a contractual basis to its clients who pay the company directly. Accordingly, Medicare, Medicaid and insurance reimbursement policy changes generally do not directly impact the company. Nevertheless, reimbursement changes in government programs, particularly Medicare and Medicaid, can and do indirectly affect the demand and the prices paid for AMN’s services.
Stiff Competition: AMN Healthcare faces significant competition in the Medical Services industry. The company competes in national, regional and local markets for healthcare organization clients and healthcare professionals. In the nurse and allied healthcare staffing business, it competes with a few national competitors, along with numerous smaller, regional and local companies.
Estimate Trend
AMN Healthcare has been witnessing a positive estimate revision trend for 2023. Over the past 90 days, the Zacks Consensus Estimate for its earnings per share has moved 0.8% north to $8.35.
The Zacks Consensus Estimate for second-quarter 2023 revenues is pegged at $987.9 million, suggesting a 30.8% decline from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Hologic, Inc. (HOLX - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Hologic, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 5.1% for fiscal 2024. HOLX’s earnings surpassed estimates in all the trailing four quarters, with an average of 27.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic has gained 9.8% compared with the industry’s 8.8% rise in the past year.
HealthEquity, sporting a Zacks Rank #1 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 9.1%.
HealthEquity has gained 0.5% against the industry’s 16.9% decline over the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.5%. BSX’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.9%.
Boston Scientific has gained 40.7% against the industry’s 22.8% decline over the past year.